A 21st century evaluation of the safety of oral vitamin D

Nutrition

Volumn 28, Issue 4, 2012, Pages 344-356

  Glade, Michael J ^a  

^a The Nutrition Doctor   (United States)

Author keywords

Safety; Upper limit of intake; Vitamin D

Indexed keywords

25 HYDROXYERGOCALCIFEROL; CALCIFEDIOL; CALCITRIOL; CALCIUM; CATHELICIDIN; COLECALCIFEROL; ERGOCALCIFEROL; INTERLEUKIN 10; OXYGENASE; PARATHYROID HORMONE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BONE DEMINERALIZATION; BONE DENSITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; FRACTURE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERTENSION; IMMUNOREGULATION; LUNG FUNCTION; MULTIPLE SCLEROSIS; MUSCULOSKELETAL FUNCTION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PERIODONTITIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RICKETS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; HUMANS; NUTRITIONAL REQUIREMENTS; PATIENT SAFETY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84858176600     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2011.11.006     Document Type: Review

References (221)

1. Norman A.W. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008, 88. 491S-9.
2. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
3. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006, 81:353-373.
4. Haussler M.R., Haussler C.A., Bartik L., Whitfield G.K., Hsieh J.C., Slater S., et al. Vitamin D receptor: Molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev 2008, 66(suppl 2):S98-112.
5. Jurutka P.W., Bartik L., Whitfield G.K., Mathern D.R., Barthel T.K., Gurevich M., et al. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands. J Bone Miner Res 2007, 22(suppl 2):V2-10.
6. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26:662-687.
7. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009, 94:26-34.
8. Holick M.F. The vitamin D epidemic and its health consequences. J Nutr 2005, 135. 2739S-48.
9. Holick M.F. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med 2008, 29:361-368.
10. Mathieu C., Gysemans C., Giulietti A., Bouillon R. Vitamin D and diabetes. Diabetologia 2005, 48:1247-1257.
11. Williams S., Malatesta K., Norris K. Vitamin D and chronic kidney disease. Ethn Dis 2009, 19(suppl 5):S5-S8. 11.
12. Knight J.A., Lesosky M., Barnett H., Raboud J.M., Vieth R. Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007, 16:422-429.
13. Khazai N., Judd S.E., Tangpricha V. Calcium and vitamin D: skeletal and extraskeletal health. Curr Rheumatol Rep 2008, 10:110-117.
14. Dietary reference intakes for calcium and vitamin D 2011, Institute of Medicine, National Academies Press, Washington, DC.
15. Yetley E.A., Brulé D., Cheney M.C., Davis C.D., Esslinger K.A., Fischer P.W., et al. Dietary reference intakes for vitamin D: justification for a review of the 1997 values. Am J Clin Nutr 2009, 89:719-727.
16. Cranney A., Weiler H.A., O'Donnell S., Puil L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. Am J Clin Nutr 2008, 88. 513S-9.
17. Ilahi M., Armas L.A., Heaney R.P. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr 2008, 87:688-691.
18. 3) in the elderly. J Clin Endocrinol Metab 2008, 93:3015-3020.
19. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008, 88. 582S-6.
20. Dawson-Hughes B., Harris S.S., Dallal G.E. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 1997, 65:67-71.
21. Zerwekh J.E. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008, 87:1087S-10891.
22. Wilkins C.H., Sheline Y.I., Roe C.M., Birge S.J., Morris J.C. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 2006, 14:1032-1040.
23. Thacher T.D., Clarke B.L. Vitamin D insufficiency. Mayo Clin Proc 2011, 86:50-60.
24. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002, 347:1151-1160.
25. Heaney R.P., Barger-Lux M.J., Dowell M.S., Chen T.C., Holick M.F. Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab 1997, 82:4111-4116.
26. Pawley N., Bischop N.J. Prenatal and infant predictors of bone health: the influence of vitamin D. Am J Clin Nutr 2004, 80(suppl). 1748S-51.
27. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
28. Holick M.F., Siris E.S., Binkley N., Beard M.K., Khan A., Katzer J.T., et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005, 90:3215-3224.
29. Wu K., Feskanich D., Fuchs C.S., Willett W.C., Hollis B.W., Giovannucci E.L. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007, 99:1120-1129.
30. Lips P., Hosking D., Lippuner K., Norquist J.M., Wehren L., Maalouf G., et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006, 260:245-254.
31. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501.
32. Mastaglia S.R., Seijo M., Muzio D., Somoza J., Nuñez M., Oliveri B. Effect of vitamin D nutritional status on muscle function and strength in healthy women aged over sixty-five years. J Nutr Health Aging 2011, 15:349-354.
33. Visser M., Deeg D.J., Lips P. Longitudinal Aging Study Amsterdam. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003, 88:5766-5772.
34. Wilkins C.H., Birge S.J., Sheline Y.I., Morris J.C. Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. J Natl Med Assoc 2009, 101:349-354.
35. Hicks G.E., Shardell M., Miller R.R., Bandinelli S., Guralnik J., Cherubini A., et al. Associations between vitamin D status and pain in older adults: the Invecchiare in Chianti study. J Am Geriatr Soc 2008, 56:785-791.
36. Bertone-Johnson E.R., Powers S.I., Spangler L., Brunner R.L., Michael Y.L., Larson J.C., et al. Vitamin D intake from foods and supplements and depressive symptoms in a diverse population of older women. Am J Clin Nutr 2011, 94:1104-1112.
37. Michaëlsson K., Baron J.A., Snellman G., Gedeborg R., Byberg L., Sundström J., et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr 2010, 92:841-848.
38. Freedman D.M., Looker A.C., Chang S.C., Graubard B.I. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007, 99:1594-1602.
39. Boot A.M., Krenning E.P. de Muinck Keizer-Schrama SM. The relation between 25-hydroxyvitamin D with peak bone mineral density and body composition in healthy young adults. J Pediatr Endocrinol Metab 2011, 24:355-360.
40. Shardell M., Hicks G.E., Miller R.R., Kritchevsky S., Andersen D., Bandinelli S., et al. Association of low vitamin D levels with the frailty syndrome in men and women. J Gerontol A Biol Sci Med Sci 2009, 64:69-75.
41. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
42. Melamed M.L., Muntner P., Michos E.D., Uribarri J., Weber C., Sharma J., et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 2008, 28:1179-1185.
43. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R., et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009, 339. b3692.
44. Birge S.J., Haddad J.G. 25-Hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest 1975, 56:1100-1107.
45. Sharkey J.R., Giuliani C., Haines P.S., Branch L.G., Busby-Whitehead J., Zohoori N. Summary measure of dietary musculoskeletal nutrient (calcium, vitamin D, magnesium, and phosphorus) intakes is associated with lower-extremity physical performance in homebound elderly men and women. Am J Clin Nutr 2003, 77:847-856.
46. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., Staehelin H.B., Bazemore M.G., Zee R.Y., et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004, 291:1999-2006.
47. Bischoff H.A., Stahelin H.B., Dick W., Akos R., Knecht M., Salis C., et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003, 18:343-351.
48. Vieth R. Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/ml). Best Pract Res Clin Endocrinol Metab 2011, 25:681-691.
49. Hollis B.W., Wagner C.L., Drezner M.K., Binkley N.C. Circulating vitamin D3 and 25-hydroxyvitamin D in humans: an important tool to define adequate nutritional vitamin D status. J Steroid Biochem Mol Biol 2007, 103:631-634.
50. Trivedi D.P., Doll R., Khaw K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003, 326:469-475.
51. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004, 116:634-639.
52. Chapuy M.C., Pamphile R., Paris E., Kempf C., Schlichting M., Arnaud S., et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002, 13:257-264.
53. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Giovannucci E., Dietrich T., Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257-2264.
54. Khaw K.T., Sneyd M.J., Compston J. Bone density parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. BMJ 1992, 305:273-277.
55. Devine A., Wilson S.G., Dick I.M., Prince R.L. Effects of vitamin D metabolites on intestinal calcium absorption and bone turnover in elderly women. Am J Clin Nutr 2002, 75:283-288.
56. Cauley J.A., Lacroix A.Z., Wu L., Horwitz M., Danielson M.E., Bauer D.C., et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008, 149:242-250.
57. Melamed M.L., Michos E.D., Post W., Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168:1629-1637.
58. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167:1730-1737.
59. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98:451-459.
60. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int J Epidemiol 1981, 10:337-341.
61. Judd S.E., Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci 2009, 338:40-44.
62. Pell J.P., Cobbe S.M. Seasonal variations in coronary heart disease. QJM 1999, 92:689-696.
63. Fiscella K., Franks P., Vitamin D. race, and cardiovascular mortality: findings from a national US sample. Ann Fam Med 2010, 8:11-18.
64. Kilkkinen A., Knekt P., Aro A., Rissanen H., Marniemi J., Heliovaara M., et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol 2009, 170:1032-1039.
65. Anderson J.L., May H.T., Horne B.D., Bair T.L., Hall N.L., Carlquist J.F., et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010, 106:963-968.
66. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008, 168:1174-1180.
67. Sun Q., Shi L., Rimm E.B., Giovannucci E.L., Hu F.B., Manson J.E., et al. Vitamin D intake and risk of cardiovascular disease in US men and women. Am J Clin Nutr 2011, 94:534-542.
68. Scragg R., Jackson R., Holdaway I.M., Lim T., Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990, 19:559-563.
69. Kim D.H., Sabour S., Sagar U.N., Adams S., Whellan D.J. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008, 102:1540-1544.
70. Pilz S., Marz W., Wellnitz B., Seelhorst U., Fahrleitner-Pammer A., Dimai H.P., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008, 93:3927-3935.
71. Zittermann A., Schleithoff S.S., Tenderich G., Berthold H.K., Korfer R., Stehle P. Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 2003, 41:105-112.
72. Garland C.F., Comstock G.W., Garland F.C., Helsing K.J., Shaw E.K., Gorham E.D. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989, 2:1176-1178.
73. Joffres M.R., Reed D.M., Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu Heart Study. Am J Clin Nutr 1987, 45:469-475.
74. Forman J.P., Giovannucci E., Holmes M.D., Bischoff-Ferrari H.A., Tworoger S.S., Willett W.C., et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007, 49:1063-1069.
75. Judd S.E., Nanes M.S., Ziegler T.R., Wilson P.W., Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2008, 87:136-141.
76. Forman J.P., Curhan G.C., Taylor E.N. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008, 52:828-832.
77. Hyppönen E., Boucher B.J., Berry D.J., Power C. 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008, 57:298-305.
78. Wang L., Manson J.E., Buring J.E., Lee I.M., Sesso H.D. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 2008, 51:1073-1079.
79. 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001, 86:1633-1637.
80. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83:754-759.
81. Björkman M., Sorva A., Risteli J., Tilvis R. Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients. Age Ageing 2008, 37:25-31.
82. Cashman K.D., Hill T.R., Cotter A.A., Boreham C.A., Dubitzky W., Murray L., et al. Low vitamin D status adversely affects bone health parameters in adolescents. Am J Clin Nutr 2008, 87:1039-1044.
83. Reinehr T., de Sousa G., Alexy U., Kersting M., Andler W. Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur J Endocrinol 2007, 157:225-232.
84. Need A.G., Horowitz M., Morris H.A., Nordin B.C. Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women. Am J Clin Nutr 2000, 71:1577-1581.
85. Freaney R., McBrinn Y., McKenna M.J. Secondary hyperparathyroidism in elderly people: combined effect of renal insufficiency and vitamin D deficiency. Am J Clin Nutr 1993, 58:187-191.
86. Bogin E., Massry S.G., Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 1981, 67:1215-1227.
87. Selvin E., Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 110:738-743.
88. Al Mheid I., Patel R., Murrow J., Morris A., Rahman A., Fike L., et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 2011, 58:186-192.
89. Poole K.E., Loveridge N., Barker P.J., Halsall D.J., Rose C., Reeve J., et al. Reduced vitamin D in acute stroke. Stroke 2006, 37:243-245.
90. Carrelli A.L., Walker M.D., Lowe H., McMahon D.J., Rundek T., Sacco R.L., et al. Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan Study. Stroke 2011, 42:2240-2245.
91. Pilz S., Dobnig H., Fischer J.E., Wellnitz B., Seelhorst U., Boehm B.O., et al. Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 2008, 39:2611-2613.
92. 3-1α-hydroxylase in the human kidney. J Am Soc Nephrol 1999, 10:2465-2473.
93. 3-1-α-hydroxylase. J Clin Endocrinol Metab 2001, 86:888-894.
94. Buell J.S., Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: preventing " D" ecline?. Mol Aspects Med 2008, 29:415-422.
95. McCann J.C., Ames B.N. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?. FASEB J 2008, 22:982-1001.
96. Dietrich T., Nunn M., Dawson-Hughes B., Bischoff-Ferrari H.A. Association between serum concentrations of 25-hydroxyvitamin D and gingival inflammation. Am J Clin Nutr 2005, 82:575-580.
97. Munger K.L., Zhang S.M., O'Reilly E., Hernán M.A., Olek M.J., Willett W.C., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
98. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
99. Rauchhaus M., Doehner W., Francis D.P., Davos C., Kemp M., Liebenthal C., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102:3060-3067.
100. Torre-Amione G., Kapadia S., Lee J., Durand J.B., Bies R.D., Young J.B., et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
101. Ohtsuka T., Hamada M., Hiasa G., Sasaki O., Suzuki M., Hara Y., et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001, 37:412-417.
102. Smolders J., Thewissen M., Peelen E., Menheere P., Cohen Tervaert J.W., Damoiseaux J., et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009, 4. e6635.
103. Newmark H.L., Newmark J. Vitamin D and Parkinson's disease-a hypothesis. Mov Disord 2007, 22:461-468.
104. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008, 65:1348-1352.
105. Evatt M.L., DeLong M.R., Kumari M., Auinger P., McDermott M.P., Tangpricha V., et al. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 2011, 68:314-319.
106. Knekt P., Kilkkinen A., Rissanen H., Marniemi J., Sääksjärvi K., Heliövaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol 2010, 67:808-811.
107. Ward K.A., Das G., Berry J.L., Roberts S.A., Rawer R., Adams J.E., et al. Vitamin D status and muscle function in post-menarchal adolescent girls. J Clin Endocrinol Metab 2009, 94:559-563.
108. Chin A., Paw M.J., de Jong N., Schouten E.G., van Staveren W.A., Kok F.J. Physical exercise or micronutrient supplementation for the wellbeing of the frail elderly? A randomised controlled trial. Br J Sports Med 2002, 36:126-131.
109. Bischoff-Ferrari H.A., Orav E.J., Dawson-Hughes B. Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Arch Intern Med 2006, 166:424-430.
110. Prince R.L., Austin N., Devine A., Dick I.M., Bruce D., Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med 2008, 168:103-108.
111. de Jong N., Chin A., Paw M.J., de Groot L.C., de Graaf C., Kok F.J., van Staveren W.A. Functional biochemical and nutrient indices in frail elderly people are partly affected by dietary supplements but not by exercise. J Nutr 1999, 129:2028-2036.
112. Schauber J., Gallo R.L. The vitamin D pathway: a new target for control of the skin's immune response?. Exp Dermatol 2008, 17:633-636.
113. Schauber J., Dorschner R.A., Coda A.B., Büchau A.S., Liu P.T., Kiken D., et al. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007, 117:803-811.
114. Di Nardo A., Vitiello A., Gallo R.L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003, 170:2274-2278.
115. Lee D.Y., Yamasaki K., Rudsil J., Zouboulis C.C., Park G.T., Yang J.M., et al. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J Invest Dermatol 2008, 128:1863-1866.
116. Murakami M., Ohtake T., Dorschner R.A., Schittek B., Garbe C., Gallo R.L. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002, 119:1090-1095.
117. Agerberth B., Charo J., Werr J., Olsson B., Idali F., Lindbom L., et al. The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000, 96:3086-3093.
118. Braff M.H., Zaiou M., Fierer J., Nizet V., Gallo R.L. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect Immun 2005, 73:6771-6781.
119. Howell M.D., Gallo R.L., Boguniewicz M., Jones J.F., Wong C., Streib J.E., et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006, 24:341-348.
120. Howell M.D., Wollenberg A., Gallo R.L., Flaig M., Streib J.E., Wong C., et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006, 117:836-841.
121. Yamasaki K., Gallo R.L. Antimicrobial peptides in human skin disease. Eur J Dermatol 2008, 18:11-21.
122. Schauber J., Gallo R.L. Expanding the roles of antimicrobial peptides in skin: alarming and arming keratinocytes. J Invest Dermatol 2007, 127:510-512.
123. 3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004, 173:2909-2912.
124. 3. FASEB J 2005, 19:1067-1077.
125. 3. J Invest Dermatol 2008, 128:816-824.
126. Schauber J., Svanholm C., Termén S., Iffland K., Menzel T., Scheppach W., et al. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signaling pathways. Gut 2003, 52:735-741.
127. Millen A.E., Tucker M.A., Hartge P., Halpern A., Elder D.E., Guerry D., et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004, 13:1042-1051.
128. Vinceti M., Pellacani G., Malagoli C., Bassissi S., Sieri S., Bonvicini F., et al. A population-based case-control study of diet and melanoma risk in northern Italy. Public Health Nutr 2005, 8:1307-1314.
129. Hunter D.J., Colditz G.A., Stampfer M.J., Rosner B., Willett W.C., Speizer F.E. Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. Ann Epidemiol 1992, 2:231-239.
130. van Dam R.M., Huang Z., Giovannucci E., Rimm E.B., Hunter D.J., Colditz G.A., et al. Diet and basal cell carcinoma of the skin in a prospective cohort of men. Am J Clin Nutr 2000, 71:135-141.
131. Gandini S., Raimondi S., Gnagnarella P., Doré J.F., Maisonneuve P., Testori A. Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 2009, 45:634-641.
132. Dietrich T., Joshipura K.J., Dawson-Hughes B., Bischoff-Ferrari H.A. Association between serum concentrations of 25-hydroxyvitamin D3 and periodontal disease in the US population. Am J Clin Nutr 2004, 80:108-113.
133. Amano Y., Komiyama K., Makishima M. Vitamin D and periodontal disease. J Oral Sci 2009, 51:11-20.
134. Black P.N., Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the Third National Health and Nutrition Examination Survey. Chest 2005, 128:3792-3798.
135. Wilk J.B., Walter R.E., Laramie J.M., Gottlieb D.J., O'Connor G.T. Framingham Heart Study genome-wide association: results for pulmonary function measures. BMC Med Genet 2007, 8(suppl 1):S8.
136. Gilbert C.R., Arum S.M., Smith C.M. Vitamin D deficiency and chronic lung disease. Can Respir J 2009, 16:75-80.
137. Smith W., Mitchell P., Leeder S.R., Wang J.J. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 1998, 116:583-587.
138. Klein R., Klein B.E., Tomany S.C., Cruickshanks K.J. Association of emphysema, gout, and inflammatory markers with long-term incidence of age-related maculopathy. Arch Ophthalmol 2003, 121:674-678.
139. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
140. Parekh N., Chappell R.J., Millen A.E., Albert D.M., Mares J.A. Association between vitamin D and age-related macular degeneration in the Third National Health and Nutrition Examination Survey, 1988 through 1994. Arch Ophthalmol 2007, 125:661-669.
141. Freedman D.M., Looker A.C., Chang S.C., Graubard B.I. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007, 99:1594-1602.
142. Shin M.H., Holmes M.D., Hankinson S.E., Wu K., Colditz G.A., Willett W.C. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 2002, 94:1301-1311.
143. 3 receptors in established human cancer cell lines in culture. Cancer Res 1982, 42:1116-1119.
144. 3 in the proliferation of a human colon cancer cell line in vitro. Anticancer Res 1987, 7:817-821.
145. Kallay E., Pietschmann P., Toyokuni S., Bajna E., Hahn P., Mazzucco K., et al. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 2001, 22:1429-1435.
146. Alvarez-Díaz S., Valle N., García J.M., Peña C., Freije J.M., Quesada V., et al. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J Clin Invest 2009, 119:2343-2358.
147. Holt P.R., Arber N., Halmos B., Forde K., Kissileff H., McGlynn K.A., et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002, 11:113-119.
148. 3 in colon cancer. J Steroid Biochem Mol Biol 2007, 103:763-767.
149. Ng K., Wolpin B.M., Meyerhardt J.A., Wu K., Chan A.T., Hollis B.W., et al. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer 2009, 101:916-923.
150. Garland C.F., Garland F.C., Gorham E.D. Can colon cancer incidence and death rates be reduced with calcium and vitamin D?. Am J Clin Nutr 1991, 54(suppl):193S-201.
151. Hartman T.J., Albert P.S., Snyder K., Slattery M.L., Caan B., Paskett E., et al. The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 2005, 135:252-259.
152. Gorham E.D., Garland C.F., Garland F.C., Grant W.B., Mohr S.B., Lipkin M., et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007, 32:210-216.
153. Grau M.V., Baron J.A., Sandler R.S., Haile R.W., Beach M.L., Church T.R., et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003, 95:1765-1771.
154. Feskanich D., Ma J., Fuchs C.S., Kirkner G.J., Hankinson S.E., Hollis B.W., et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004, 13:1502-1508.
155. Platz E.A., Hankinson S.E., Hollis B.W., Colditz G.A., Hunter D.J., Speizer F.E., et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev 2000, 9:1059-1065.
156. Slattery M.L., Neuhausen S.L., Hoffman M., Caan B., Curtin K., Ma K.N., et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 2004, 111:750-756.
157. Wei M.Y., Garland C.F., Gorham E.D., Mohr S.B., Giovannucci E. Vitamin D and prevention of colorectal adenoma: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2008, 17:2958-2969.
158. Lee J.E., Li H., Chan A.T., Hollis B.W., Lee I.M., Stampfer M.J., et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev Res 2011, 4:735-743.
159. Ma Y., Zhang P., Wang F., Yang J., Liu Z., Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 2011, 29:3775-3782.
160. Peters U., McGlynn K.A., Chatterjee N., Gunter E., Garcia-Closas M., Rothman N., et al. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2001, 10:1267-1274.
161. 3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 2000, 9:265-270.
162. 3. Cancer Epidemiol Biomarkers Prev 1998, 7:391-395.
163. 3 on primary cultures of human prostatic cells. Cancer Res 1994, 54:805-810.
164. Li H., Stampfer M.J., Hollis J.B., Mucci L.A., Gaziano J.M., Hunter D., et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007, 4. e103.
165. Tuohimaa P., Tenkanen L., Ahonen M., Lumme S., Jellum E., Hallmans G., et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004, 108:104-108.
166. Tuohimaa P., Tenkanen L., Syvälä H., Lumme S., Hakulinen T., Dillner J., et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:302-307.
167. Kristal A.R., Arnold K.B., Schenk J.M., Neuhouser M.L., Goodman P., Penson D.F., et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008, 167:925-934.
168. Tretli S., Hernes E., Berg J.P., Hestvik U.E., Robsahm T.E. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009, 100:450-454.
169. Fang F., Kasperzyk J.L., Shui I., Hendrickson W., Hollis B.W., Fall K., et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One 2011, 6. e18625.
170. Albanes D., Mondul A.M., Yu K., Parisi D., Horst R.L., Virtamo J., et al. Serum 25-hydroxyvitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev 2011, 20:1850-1860.
171. Ahn J., Albanes D., Berndt S.I., Peters U., Chatterjee N., Freedman N.D., et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009, 30:769-776.
172. Torkko K.C., van Bokhoven A., Mai P., Beuten J., Balic I., Byers T.E., et al. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res 2008, 14:3223-3229.
173. Holick C.N., Stanford J.L., Kwon E.M., Ostrander E.A., Nejentsev S., Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:1990-1999.
174. Cicek M.S., Liu X., Schumacher F.R., Casey G., Witte J.S. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:2549-2552.
175. Tayeb M.T., Clark C., Haites N.E., Sharp L., Murray G.I., McLeod H.L. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003, 88:928-932.
176. Yin M., Wei S., Wei Q. Vitamin D receptor genetic polymorphisms and prostate cancer risk: a meta-analysis of 36 published studies. Int J Clin Exp Med 2009, 2:159-175.
177. Kakarala R.R., Chandana S.R., Harris S.S., Kocharla L.P., Dvorin E. Prevalence of vitamin D deficiency in uninsured women. J Gen Intern Med 2007, 22:1180-1183.
178. Nesby-O'Dell S., Scanlon K.S., Cogswell M.E., Gillespie C., Hollis B.W., Looker A.C., et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002, 76:187-192.
179. Semba R.D., Garrett E., Johnson B.A., Guralnik J.M., Fried L.P. Vitamin D deficiency among older women with and without disability. Am J Clin Nutr 2000, 72:1529-1534.
180. Lappe J.M., Davies K.M., Travers-Gustafson D., Heaney R.P. Vitamin D status in a rural postmenopausal female population. J Am Coll Nutr 2006, 25:395-402.
181. Wang-Gillam A., Miles D.A., Hutchins L.F. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist 2008, 13:821-827.
182. McCullough M.L., Robertson A.S., Rodriguez C., Jacobs E.J., Chao A., Carolyn J., et al. Calcium, vitamin D, dairy products, and risk of colorectal cancer in the cancer prevention study II nutrition cohort (United States). Cancer Causes Control 2003, 14:1-12.
183. Orwoll E., Nielson C.M., Marshall L.M., Lambert L., Holton K.F., Hoffman A.R., et al. Vitamin D deficiency in older men. J Clin Endocrinol Metab 2009, 94:1214-1222.
184. Kumari M., Judd S.E., Tangpricha V. Vitamin D status in United States war veterans. Endocr Pract 2008, 14:127-128.
185. Hirani V., Primatesta P. Vitamin D concentrations among people aged 65 years and over living in private households and institutions in England: population survey. Age Ageing 2005, 34:485-491.
186. Ginde A.A., Liu M.C., Camargo C.A. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009, 169:626-632.
187. Looker A.C., Pfeiffer C.M., Lacher D.A., Schleicher R.L., Picciano M.F., Yetley E.A. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008, 88:1519-1527.
188. Renzaho A.M., Halliday J.A., Nowson C., Vitamin D. obesity, and obesity-related chronic disease among ethnic minorities: a systematic review. Nutrition 2011, 27:868-879.
189. Barger-Lux M.J., Heaney R.P., Dowell S., Chen T.C., Holick M.F. Vitamin D and its major metabolites: Serum levels after graded oral dosing in healthy men. Osteoporos Int 1998, 8:222-230.
190. Jacobs E.T., Alberts D.S., Foote J.A., Green S.B., Hollis B.W., Yu Z., et al. Vitamin D insufficiency in southern Arizona. Am J Clin Nutr 2008, 87:608-613.
191. Pepper K.J., Judd S.E., Nanes M.S., Tangpricha V. Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. Endocr Pract 2009, 15:95-103.
192. 3. J Am Coll Nutr 2002, 21:357-362.
193. Gertner J.M., Domenech M. 25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol. J Clin Pathol 1977, 30:144-150.
194. Cashman K.D., Wallace J.M., Horigan G., Hill T.R., Barnes M.S., Lucey A.J., et al. Estimation of the dietary requirement for vitamin D in free-living adults >=64 y of age. Am J Clin Nutr 2009, 89:1366-1374.
195. Cashman K.D., Hill T.R., Lucey A.J., Taylor N., Seamans K.M., Muldowney S., et al. Estimation of the dietary requirement for vitamin D in healthy adults. Am J Clin Nutr 2008, 88:1535-1542.
196. Hollis B.W., Johnson D., Hulsey T.C., Ebeling M., Wagner C.L. Vitamin D supplementation during pregnancy: double blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res 2011, 26:2341-2357.
197. Heaney R.P., Davies K.M., Chen T.C., Holick M.F., Barger-Lux M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77:204-210.
198. Hathcock J.N., Shao A., Vieth R., Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007, 85:6-18.
199. Pettifor J.M., Bikle D.D., Cavaleros M., Zachen D., Kamdar M.C., Ross F.P. Serum levels of free 1,25-dihydroxyvitamin D in vitamin D toxicity. Ann Intern Med 1995, 122:511-513.
200. Koutkia P., Chen T.C., Holick M.F. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 2001, 345:66-67.
201. 3: effects on biochemical parameters in two men. Ann Clin Biochem 2008, 45:106-110.
202. Hollis B.W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005, 135:317-322.
203. Mason R.S., Lissner D., Grunstein H.S., Posen S. A simplified assay for dihydroxylated vitamin D metabolites in human serum: application to hyper- and hypovitaminosis D. Clin Chem 1980, 26:444-450.
204. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Hu F.B., Zhang Y., Karlson E.W., et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr 2004, 80:752-758.
205. Barger-Lux M.J., Heaney R.P. Effects of above average summer sun exposure on serum 25-hydroxyvitamin D and calcium absorption. J Clin Endocrinol Metab 2002, 87:4952-4956.
206. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999, 69:842-856.
207. 3 given to overweight subjects for one year. Nutr J 2010, 9:1.
208. Sneve M., Figenschau Y., Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol 2008, 159:675-684.
209. Amir E., Simmons C.E., Freedman O.C., Dranitsaris G., Cole D.E., Vieth R., et al. A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer 2010, 116:284-291.
210. Smolders J., Peelen E., Thewissen M., Cohen Tervaert J.W., Menheere P., Hupperts R., et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010, 5. e15235.
211. Stern P.H., Taylor A.B., Bell N.H., Epstein S. Demonstration that circulating 1α,25-dihydroxyvitamin D is loosely regulated in normal children. J Clin Invest 1981, 68:1374-1377.
212. Stamp T.C. Factors in human vitamin D nutrition and in the production and cure of classical rickets. Proc Nutr Soc 1975, 34:119-130.
213. Armas L.A., Hollis B.W., Heaney R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004, 89:5387-5391.
214. Khaw K.T., Scragg R., Murphy S. Single-dose cholecalciferol suppresses the winter increase in parathyroid hormone concentrations in healthy older men and women: a randomized trial. Am J Clin Nutr 1994, 59:1040-1044.
215. El-Hajj Fuleihan G., Nabulsi M., Tamim H., Maalouf J., Salamoun M., Khalife H., et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab 2006, 91:405-412.
216. 3 supplementation in school children. J Clin Endocrinol Metab 2008, 93:2693-2701.
217. Arpadi S.M., McMahon D., Abrams E.J., Bamji M., Purswani M., Engelson E.S., et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics 2009, 123:e121-e126.
218. Sanders K.M., Stuart A.L., Williamson E.J., Simpson J.A., Kotowicz M.A., Young D., et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303:1815-1822.
219. 3 in adults with multiple sclerosis. Am J Clin Nutr 2007, 86:645-651.
220. Hathcock J.N., Shao A. Expanded approach to tolerable upper intake guidelines for nutrients and bioactive substances. J Nutr 2008, 138. 1992S-5.
221. A model for establishing upper levels of intake for nutrients and related substances. Report of a joint FAO/WHO technical workshop on nutrient risk assessment 2005, FAO/WHO, World Health Organization, Geneva.